Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

Completed · Phase 4 · Has a placebo group

Conditions studied: Eosinophilic Esophagitis

In brief

Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms, which medication provides a more durable treatment response, and whether biomarkers can predict treatment response. Participants: A total of up to 200 16-80 year old patients with a new diagnosis of eosinophilic esophagitis (EoE) who are referred for upper endoscopy will be consented with a target of 122 randomized. Procedures: This will be a prospective, randomized, double-blind, double-dummy, clinical trial comparing OVB to fluticasone MDI for treatment of EoE. This overall study design will generate data for all three Aims

Key facts

Study ID
NCT02019758
Run by
University of North Carolina, Chapel Hill
People needed
129
Starts
2015-01-01
Expected to finish
2019-04-01
Last updated by the study team
2020-04-27

Who can join

Age: 16 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.